Maia Biotechnology Inc
NYSE American:MAIA

  • LAST PRICE
    2.0900
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    2.0000/ 16
  • Ask / Lots
    2.2000/ 2
  • Open / Previous Close
    --- / 2.0900
  • Day Range
    ---
  • 52 Week Range
    0.8200
    5.9900
  • Volume
    21

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 7, 2024

      Show headlines and story abstract

    • 8:47AM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: MAIA

      MAIA Biotechnology Announces Participation by Director Stan Smith, Ph.D. in Recent Private Placement
      CHICAGO--(BUSINESS WIRE)--November 07, 2024--
      MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Stan V. Smith, Ph.D. made an individual purchase of 100,000 shares of MAIA's common stock, and warrants to purchase 100,000 shares, of MAIA's common stock for an aggregate purchase price of $225,900 as part of the Company's recent private placement of common stock and warrants announced by the Company on October 28, 2024, and which closed on November 1, 2024.

  • Nov 5, 2024

  • Oct 28, 2024

      Show headlines and story abstract

    • 7:00PM ET on Monday Oct 28, 2024 by Dow Jones
      Companies Mentioned: MAIA

      MAIA Biotechnology Announces $2.44 Million Private Placement
      CHICAGO--(BUSINESS WIRE)--October 28, 2024--
      MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,079,784 shares of common stock at a purchase price of $2.259 per share, in a private placement to accredited investors and certain Company directors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.51 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed (subject to customary adjustments as set forth in the warrants). The warrants are exercisable commencing six months following issuance and have a term of five years from the initial exercise date. The securities being sold to the Company director participating in the offering are being issued pursuant to the Company's 2021 Equity Incentive Plan. The private placement is expected to close on or about October 30, 2024, subject to the satisfaction of customary closing conditions.

Peers Headlines